Literature DB >> 10548527

Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis.

B M Schreiber1, M Veverbrants, R E Fine, J K Blusztajn, M Salmona, A Patel, J D Sipe.   

Abstract

The addition of acute-phase apolipoprotein serum amyloid A (SAA) to cultured aortic smooth-muscle cells caused a decrease in the incorporation of [(14)C]acetate into lipids. Optimal inhibition of lipid biosynthesis was achieved with 2 microM SAA, and the effect was maintained for up to 1 week when SAA was included in the culture medium. Lipid extracts were subjected to TLC and it was determined that the SAA-induced decrease in [(14)C]acetate incorporation into lipids was attributable to decreases in cholesterol, phospholipid and triglyceride levels. The accumulated mass of cholesterol and phospholipid in SAA-treated cultures was significantly less than that of controls, with no change in the accumulated protein. Moreover, SAA had no effect on either protein synthesis or DNA synthesis, suggesting that SAA specifically alters lipid synthesis. By using a peptide corresponding to the cholesterol-binding domain of acute-phase SAA (amino acids 1-18), it was shown that this region of the molecule was as effective as the full-length protein in decreasing lipid synthesis and the accumulation of cholesterol and phospholipid. The implications of these findings for atherosclerosis and Alzheimer's disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548527      PMCID: PMC1220607     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  56 in total

1.  Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells.

Authors:  J S Liang; B M Schreiber; M Salmona; G Phillip; W A Gonnerman; F C de Beer; J D Sipe
Journal:  J Lipid Res       Date:  1996-10       Impact factor: 5.922

2.  Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis.

Authors:  C Tape; R Kisilevsky
Journal:  Biochim Biophys Acta       Date:  1990-04-17

Review 3.  Amyloidosis: a final common pathway for protein deposition in tissues.

Authors:  M J Stone
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

4.  beta-VLDL-induced alterations in growth potentiating activity produced by mononuclear phagocytes.

Authors:  B M Schreiber; B M Martin; W Hollander; C Franzblau
Journal:  Atherosclerosis       Date:  1988-01       Impact factor: 5.162

5.  Phosphorylation of human serum amyloid A protein by protein kinase C.

Authors:  A E Nel; M C De Beer; E G Shephard; A F Strachan; M L Vandenplas; F C De Beer
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

6.  Evidence for qualitative abnormalities in high-density lipoproteins from myeloma patients: the presence of amyloid A protein could explain HDL modifications.

Authors:  H Hachem; G Favre; G Soula
Journal:  Biochim Biophys Acta       Date:  1988-11-25

7.  Time course of serum amyloid A response in myocardial infarction.

Authors:  L L Bausserman; A Sadaniantz; A L Saritelli; V L Martin; A M Nugent; S P Sady; P N Herbert
Journal:  Clin Chim Acta       Date:  1989-10-16       Impact factor: 3.786

8.  Influence of serum amyloid A on cholesterol esterification in human plasma.

Authors:  A Steinmetz; G Hocke; R Saïle; P Puchois; J C Fruchart
Journal:  Biochim Biophys Acta       Date:  1989-11-28

9.  Elevation of C-reactive protein in "active" coronary artery disease.

Authors:  B C Berk; W S Weintraub; R W Alexander
Journal:  Am J Cardiol       Date:  1990-01-15       Impact factor: 2.778

10.  Serum amyloid A protein, apolipoprotein A-I, and apolipoprotein B during the course of acute myocardial infarction.

Authors:  C P Maury; K J Tötterman; C G Gref; C Ehnholm
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

View more
  6 in total

1.  Trafficking of endogenous smooth muscle cell cholesterol: a role for serum amyloid A and interleukin-1β.

Authors:  Lawrence G Pessolano; Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Laura Liscum; Phillip J Stone; Jean D Sipe; Barbara M Schreiber
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-20       Impact factor: 8.311

2.  Proteomic analysis of human serum for finding pathogenic factors and potential biomarkers in preeclampsia.

Authors:  C Liu; N Zhang; H Yu; Y Chen; Y Liang; H Deng; Z Zhang
Journal:  Placenta       Date:  2010-12-08       Impact factor: 3.481

3.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

4.  Serum Amyloid A Induces a Vascular Smooth Muscle Cell Phenotype Switch through the p38 MAPK Signaling Pathway.

Authors:  Xincai Zhang; Jinqin Chen; Shixun Wang
Journal:  Biomed Res Int       Date:  2017-05-31       Impact factor: 3.411

5.  Expression and Differential Responsiveness of Central Nervous System Glial Cell Populations to the Acute Phase Protein Serum Amyloid A.

Authors:  Massimo Barbierato; Mila Borri; Laura Facci; Morena Zusso; Stephen D Skaper; Pietro Giusti
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

6.  Serum amyloid A inhibits dendritic cell differentiation by suppressing GM-CSF receptor expression and signaling.

Authors:  Ji Cheol Kim; Young Su Jung; Ha Young Lee; Joon Seong Park; Yoe-Sik Bae
Journal:  Exp Mol Med       Date:  2017-08-25       Impact factor: 8.718

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.